University at Buffalo - The State University of New York
Skip to Content
Qing                           Ma

Qing Ma PhD

Department of Pharmacy Practice

Assistant Professor

 
Professional Summary:

Research interests areas:

1. Pharmacogenomics of antiretrovirals in patients with HIV-associated neurocognitive disorders

2. Mechanisms of drug-drug interactions in patients with HIV infection

3. Incorporating pharmacokinetics, pharmacodynamics and pharmacogenomics in studying the effects of antiretrovirals on the central nervous system

Education and Training:
  • PhD, Loyola University Chicago (2003)
  • BS, West China University of Medical Sciences (1995)
Employment:
  • Assistant Professor of Pharmacy Practice, Pharmacy Practice, University at Buffalo (2013-present)
  • Adjunct Assistant Professor of Pharmacology and Physiology, University of Rochester (2012-present)
  • Research Scientist, Translational Pharmacology Research Core, University at Buffalo, New York State Center of Excellence in Bioinformatics and Life Sciences (2006-present)
  • Research Assistant Professor, University at Buffalo (2006–2013)
  • Fellow, University at Buffalo (2004–2005)
Awards and Honors:
  • Research Mentor of the Year (2012)
  • Visiting Scholar (2010)
  • Visiting Professor (2008)
  • Conference Scholarship (2007)
  • George McCracken Infectious Disease Fellow (2005)
  • George McCracken Infectious Disease Fellow (2004)
  • Travel Award (2004)
  • Young Investigator Award (2003)
  • Graduate Travel Award (2002)

Grants and Sponsored Research:
  • June 2012–June 2017
    Antiretroviral pharmacogenomics, pharmacokinetics and toxicity in neuroAIDS
    NIH
    Role: Principal Investigator
    $598,880

Journal Articles:
See all (26 more)
Abstracts:
  • Mudzviti T; Maponga C; Khoza S; Tagwireyi D; Ma Q; Morse ED. Adverse Drug Reactions During Antiretroviral Therapy in Zimbabwe. 37th Annual International Conference on Global Health. 2010.
  • Maponga C; DiFrancesco R; Tooley KM; Jaravani P; Ma Q; Morse ED. Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research In Southern African Countries. 18th International AIDS Conference (AIDS 2010). 2010.
  • Venuto C; Ma Q; Morse ED. Effects of CYP2B6 single nucleotide polymorphism (SNPs) and substance abude on efavirenz (EFV) pharmacokinetics. UB Celebration of Academic Excellence. 2010.
  • Ma Q; Tooley KM; Welliver R; Condino D; Lliguicota F; Maponga C; DiFrancesco R; Morse ED; Sulaimen A; Felton C; Sawyer JR; Mudzviti T; Hsiao CB; Walshe K; Gbadamosi F; Sayidine F. Developing an International Health Information Technology Network for HIV Medication Management Research. NY HIV Research Centers Consortium. 2010.
  • Venuto C; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman RC; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics. ICAAC Conference. 2009.
  • Acheampong F; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Relationship between CYP3A5 Nucleotide Polymorphisms and Protease Inhibitor Trough Concentrations in HIV+ Patients during Therapeutic Drug Monitoring. ICAAC Conference. 2009.
  • Fehintola F; Ma Q; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A; Morse ED. Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals. ICAAC Conference. 2009.
  • Ma Q; Forrest A; Rosenkranz S; Para M; Adams E; Yaresheski K; Reichman RC; Morse ED; A. Optimal multidrug PK and sampling strategies (OSS) for efavirenz and indinavir. 2005 Annual Meeting of the American Society of Clinical Pharmacology & Therapeutics. 2005.
  • Zack J; A; Forrest A; Ma Q; Rosenkranz S; Para MF; Adams E; Yaresheski K; Reichman RC; Morse ED. Optimal Sparse Pharmacokinetic Sampling Strategies for Multi-Drug Antiretroviral Regimens. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. 2005.

Professional Memberships:
  • International AIDS Society (2006)
  • American Society of Microbiology (2004)
  • Society of Infectious Diseases Pharmacists (2004)
  • American Society for Clinical Pharmacology and Therapeutics; Award Committee Member, Education Committee Member (2001)
  • American Society for Clinical Pharmacology and Therapeutics (2000–present)
  • American Pharmacist Association (1999)
Presentations:
  • "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference (IAS AIDS 2012), IAS AIDS (2012)
  • "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" ACTG Conference, ACTG (2012)
  • "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference (2012)
  • "Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202" XIX International AIDS Conference (AIDS/IAS 2012), IAS AIDS (2012)
  • "Tenofovir plasma pharmacokinetics in AIDS Clinical Trials Group Study A5202." XIX International AIDS Conference (2012)
  • "Comparison of modeled and non-modeled clearances for efeavirenz" Translational Science 2012 (2012)
  • "Pharmacogenomics of CYP3A: Considerations for HIV Treatment" 5th Health Disparities Conference, Xavier University of Louisiana (2012)
  • "A Physiological Pharmacokinetic Model Characterizes Efavirenz Metabolic Induction in HIV-Infected Ugandan Patients" 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2011)
  • "Pharmacokinetics of efavirenz among HIV infected Ugandans" 12th International Workshop on Clinical Pharmacology of HIV Thearpy (2011)
  • "Establishing A Health Information Technology Network for HIV/TB Medication Management Research" DCFAR 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
  • "Interindividual Variability of ABCB1 Expression in Peripheral Blood Mononuclear Cells from HIV-Infected Patients" 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2010)
  • "Pharmaceutical Safety Initiative: Enhancing Patient Safety with Information Technology and Biomedical Informatics" Pharmacy Safety Forum, New York Department of Health - Patient Safety Center (2010)
  • "Developing an International Health Information Technology Network for HIV Medication Management Research" NY HIV Research Centers Consortium 2010 Scientific Conference (2010)
  • "Update on pharmacotherapy for pediatric HIV infection" 13th Asian Pacific Congress of Pediatrics (2009)
  • "Effects of CYP2B6 single nucleotide polymorphisms and substance abuse on efavirenz pharmacokinetics" 49th ICAAC, ASM (2009)
  • "Inter-individual variability of atazanavir plasma concentrations in HIV patients" 49th ICAAC, ASM (2009)
  • "Relationship between CYP3A5 single nucleotide polymorphisms and protease inhibitor trough concentrations in HIV+ patients during therapeutic drug monitoring" 49th ICAAC, ASM (2009)
  • "Tobacco and marijuana uses significantly decrease atazanavir trough concentrations in HIV infected individuals" 49th ICAAC, ASM (2009)
  • "Comparison of antiretroviral pharmacokinetics and clinical monitoring parameters in HIV-infected patients with and without substance abuse" 16th Conference on Retroviruses and Opportunistic Infections (2009)
  • "Clinical and Translational Pharmacogenomics: Integrating a Seminar Program with UndergraduatePharmacogenomics Research" ACCP Annual Meeting, American College of Clinical Pharmacy (2008)
  • "Determining the rate, nature and predictors of adverse drug reactions associated with the use of highly active antiretroviral therapy (HAART) in a resource limited setting (Zimbabwe)" The IXth World Conference on Clinical Pharmacology and Therapeutics (2008)
  • "Effect of CYP3A5 polymorphisms on atazanavir and lopinavir trough concentrations in HIV-infected substance abusers" 9th International Workshop on Clinical Pharmacology of HIV Therapy (2008)
  • "An Appropriate Structural and Population Pharmacokinetic (PK) Model for Atazanavir (ATV)" ICAAC (2007)
  • "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" ICAAC (2007)
  • "Therapeutic Drug Monitoring and Inhibitory Quotients in HIV-Infected Substance Users and Non-substance Users Receiving HIV-1 Protease Inhibitors" CROI 2007 (2007)
  • "CYP3A5 polymorphisms in HIV-infected substance users and nonusers during therapeutic drug monitoring" 49th Annual Meeting of ICAAC (2006)
  • "MDR1 Polymorphisms, Therapeutic Drug Monitoring, Protease Inhibitors" CROI (2006)
  • "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" 45th Annual ICAAC (2005)
See all (18 more)
Service Activities:
  • Neurology Collaborative Science Group Scientific Committee; AIDS Clinical Trip Group; Member (2012)
  • Chinese Clinical Pharmacy Collaboration; Communication between Chinese pharmacy schools and UB, development of MOU; Coordinator (2011)
  • Education Committee; American Society for Clinical Pharmacology and Therapeutics Education Committee Award Committee; Other (2008)

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
315 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 881-7500
Fax: NA
Email: qingma@buffalo.edu


Log in to Update Your Profile